The End of an Era: Lipitor, Blockbuster Drugs and the Waxman/Hatch Model
By
Michael McCaughan / Email the Author / The RPM Report December 2011, Vol. 8, No. 1
Feature Articles / Word Count: 3978 / Article # 2012500009
Executive Summary
Pfizer’s Lipitor goes generic—albeit with some decidedly unusual wrinkles. The biggest generic launch in history is a good moment to take stock of the transition away from the blockbuster model. The reaction to the milestone suggests that the industry’s critics may be having a harder time letting go of the old model than industry is.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.